
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

March 2, 2020

Commission File Number 001-35203

THERATECHNOLOGIES INC.

(Translation of registrant's name into English)

2015 Peel Street, Suite 1100
Montréal, Québec, Canada
H3A 1T8
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.

THERATECHNOLOGIES INC.

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release Dated March 2, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THERATECHNOLOGIES INC.

By: /s/ Jocelyn Lafond

Name: Jocelyn Lafond

Title: Vice President, Legal Affairs

Date: March 2, 2020



CHANGE TO THERATECHNOLOGIES MANAGEMENT

Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring

Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who is retiring after a 23-year career. Mr. Tanguay will remain available to ensure a smooth transition.

“Theratechnologies is at a turning point in its history. I am extremely proud to join this team and leverage my knowledge and expertise to ensure the company’s continued growth, as well as to harness its full potential,” said Mr. Lévesque. “One of my main goals is to bring Trogarzo to people living with HIV. Trogarzo, whose approval has already been fast tracked, is a breakthrough drug designed to meet an unmet medical need.”

Paul Lévesque boasts over 30 years of experience in the pharmaceutical field. After beginning his career in 1985 at UpJohn in Montreal, he joined Pfizer Canada in 1992, then Pfizer France in 2002, where he held various positions, eventually serving as president of Pfizer Canada from 2007 to 2012. Since then, he has held several marketing and executive positions at Pfizer headquarters in New York, as part of which he had international responsibilities, notably in Asia-Pacific and in the United States. Mr. Lévesque is and will remain the Global President of Pfizer Rare Disease until he takes up his position at Theratechnologies.

“We are thrilled that Paul Lévesque is joining the company. On behalf of the board and management, we look forward to working with him and benefiting from his considerable experience in the global commercialization of pharmaceutical products,” said Dawn Svoronos, Chair of the Board of Directors.

Theratechnologies would like to take this opportunity to recognize the immense contribution of Luc Tanguay, who skillfully led the company’s critical restructuring initiatives through his leadership and innovative vision.

“On behalf of the board of directors, management and shareholders, the company thanks Luc for his close collaboration with board members and wishes him a well-deserved retirement,” added Ms. Svoronos.

Mr. Tanguay, who has been involved in the biotechnology industry for over 20 years, has been a member of the Theratechnologies management team since 1996. As President and CEO since 2012, Mr. Tanguay has transformed the company into a fully integrated business operating in the United States, Canada and Europe, with a significant research and development portfolio.

“It was an honour to be able to make a significant contribution to the growth of Theratechnologies,” said Mr. Tanguay. “I am proud to leave Theratechnologies by handing over a company with a solid infrastructure and financial health to my successor. I would like to thank the loyal and high-performing management team members who have contributed to the company’s success over the past few years. I have no doubt that they will be able to support Paul Lévesque and help him build on this momentum.”

ABOUT THERATECHNOLOGIES

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov

-30-

INFORMATION AND INTERVIEW REQUESTS:

Marie-Christine Garon
NATIONAL Public Relations
514-409-0031
mcgaron@national.ca